BR0314512A - Célula hospedeira recombinante procariótica, método para a produção de um plasmìdeo, plasmìdeo e método para a detecção de uma mutação de cópia plasmìdea - Google Patents

Célula hospedeira recombinante procariótica, método para a produção de um plasmìdeo, plasmìdeo e método para a detecção de uma mutação de cópia plasmìdea

Info

Publication number
BR0314512A
BR0314512A BR0314512-3A BR0314512A BR0314512A BR 0314512 A BR0314512 A BR 0314512A BR 0314512 A BR0314512 A BR 0314512A BR 0314512 A BR0314512 A BR 0314512A
Authority
BR
Brazil
Prior art keywords
plasmid
host cell
detecting
producing
recombinant host
Prior art date
Application number
BR0314512-3A
Other languages
English (en)
Inventor
Fabienne Soubrier
Original Assignee
Centelion
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion, Aventis Pharma Inc filed Critical Centelion
Publication of BR0314512A publication Critical patent/BR0314512A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)

Abstract

"CéLULA HOSPEDEIRA RECOMBINANTE PROCARIóTICA, MéTODO PARA A PRODUçãO DE UM PLASMìDEO, PLASMìDEO E MéTODO PARA A DETECçãO DE UMA MUTAçãO DE CóPIA PLASMìDEA". A presente invenção trata de célula hospedeira recombinante procariótica compreendendo uma proteína de iniciação de replicação heteróloga que ativa uma origem condicional de replicação e uma molécula DNA extracromossómica que compreende um gene terapêutico heterólogo e uma origem condicional de replicação, cuja funcionalidade na célula hospedeira recombinante procariótica requer uma proteína de iniciação de replicação estranha à célula hospedeira.
BR0314512-3A 2002-10-11 2003-10-14 Célula hospedeira recombinante procariótica, método para a produção de um plasmìdeo, plasmìdeo e método para a detecção de uma mutação de cópia plasmìdea BR0314512A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/268,948 US7279313B2 (en) 1995-09-15 2002-10-11 Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
PCT/US2003/032512 WO2004033664A2 (en) 2002-10-11 2003-10-14 Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy

Publications (1)

Publication Number Publication Date
BR0314512A true BR0314512A (pt) 2005-07-26

Family

ID=32092417

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314512-3A BR0314512A (pt) 2002-10-11 2003-10-14 Célula hospedeira recombinante procariótica, método para a produção de um plasmìdeo, plasmìdeo e método para a detecção de uma mutação de cópia plasmìdea

Country Status (22)

Country Link
US (3) US7279313B2 (pt)
EP (1) EP1549735B1 (pt)
JP (2) JP4522861B2 (pt)
KR (1) KR101323542B1 (pt)
CN (2) CN100491521C (pt)
AT (1) ATE521695T1 (pt)
AU (2) AU2003287078B2 (pt)
BR (1) BR0314512A (pt)
CA (1) CA2501851C (pt)
CY (1) CY1112110T1 (pt)
DK (1) DK1549735T3 (pt)
ES (1) ES2372599T3 (pt)
HK (1) HK1082761B (pt)
IL (1) IL167706A (pt)
MX (1) MXPA05003857A (pt)
NO (1) NO333932B1 (pt)
NZ (2) NZ539311A (pt)
PT (1) PT1549735E (pt)
RU (1) RU2307870C2 (pt)
SI (1) SI1549735T1 (pt)
WO (1) WO2004033664A2 (pt)
ZA (1) ZA200503039B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038026B2 (en) * 2000-05-26 2006-05-02 Centelion Purification of a triple heli formation with an immobilized oligonucleotide
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
EP2246413A3 (en) 2004-04-19 2011-10-26 Centelion Method for purifying plasmid DNA having pharmaceutical quality
RU2306338C2 (ru) * 2004-06-24 2007-09-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Mob'-ПРОИЗВОДНАЯ ПЛАЗМИДА RSF1010, НЕ СОДЕРЖАЩАЯ ГЕНЫ УСТОЙЧИВОСТИ К АНТИБИОТИКАМ, БАКТЕРИЯ, СОДЕРЖАЩАЯ УКАЗАННУЮ ПЛАЗМИДУ, И СПОСОБ ПОЛУЧЕНИЯ ПОЛЕЗНЫХ МЕТАБОЛИТОВ
JP4581851B2 (ja) * 2004-07-27 2010-11-17 セイコーエプソン株式会社 電気光学装置の駆動回路及び駆動方法、電気光学装置並びに電子機器
FR2920158B1 (fr) * 2007-08-24 2010-03-12 Centre Nat Rech Scient Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
EP2221066A1 (en) 2009-02-18 2010-08-25 Sanofi-Aventis Use of VgII3 activity modulator for the modulation of adipogenesis
EP2471909A1 (en) * 2010-12-30 2012-07-04 SIRION BIOTECH GmbH Nucleic acid molecules for generating adenoviral vectors
JP5863338B2 (ja) 2011-08-25 2016-02-16 株式会社東芝 プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット
US9550998B2 (en) 2012-08-29 2017-01-24 Nature Technology Corporation DNA plasmids with improved expression
US20150322439A1 (en) 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
WO2016080424A1 (ja) * 2014-11-18 2016-05-26 国立研究開発法人 科学技術振興機構 環状ｄｎａの増幅方法
JP7014721B2 (ja) 2015-09-18 2022-02-01 ディーエヌエーアールエックス インビボでの核酸発現のためのシステム及び方法
KR102423442B1 (ko) 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
EP3600428A4 (en) * 2017-03-23 2020-08-26 Dnarx SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO
WO2019183248A1 (en) 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
AU2019315179B2 (en) * 2018-07-30 2023-02-02 OriCiro Genomics, Inc. Method for editing dna in cell-free system
CA3127031A1 (en) * 2019-01-18 2020-07-23 Janssen Biotech, Inc. .beta.-galactosidase alpha peptide as a non-antibiotic selection marker and uses thereof
CN114450408A (zh) * 2019-09-25 2022-05-06 鲁汶天主教大学 大载体和用于高产量生产的方法
WO2023069895A1 (en) * 2021-10-18 2023-04-27 Modernatx, Inc. Markerless dna production
US20250354159A1 (en) * 2022-06-13 2025-11-20 Nanjing GenScript Biotech Co., Ltd. Wild-type-mutant pi protein switching expression system capable of increasing efficiency of preparing screening-tag-free plasmid
WO2025160245A1 (en) 2024-01-25 2025-07-31 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2025208072A1 (en) * 2024-03-29 2025-10-02 The General Hospital Corporation Methods and materials for treating disorders related to bacterial infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4654307A (en) 1983-02-17 1987-03-31 The Research Foundation Of State University Of New York Novel bacteria containing a plasmid having a tRNA code
US4761367A (en) 1984-11-07 1988-08-02 The University Of North Carolina At Chapel Hill Vectors suitable for detection of eukaryotic DNA regulatory sequences
US5859208A (en) 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5198343A (en) * 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US5510099A (en) 1987-05-01 1996-04-23 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
RU2107725C1 (ru) * 1989-02-24 1998-03-27 Монсанто Компани Способ модификации фрагмента днк, кодирующего инсектицидный белок bacillus thuringiensis, фрагмент днк, кодирующий инсектицидный белок bacillus thuringiensis (варианты), фрагмент днк, содержащий структурный ген, кодирующий инсектицидный белок (варианты), и фрагмент днк, содержащий структурный ген, кодирующий слитый белок
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5512463A (en) * 1991-04-26 1996-04-30 Eli Lilly And Company Enzymatic inverse polymerase chain reaction library mutagenesis
TW201794B (pt) * 1991-05-03 1993-03-11 American Cyanamid Co
US5714323A (en) 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
US5444149A (en) 1992-05-11 1995-08-22 Duke University Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation
US5434065A (en) 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5700657A (en) 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
IL109558A (en) 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
AU2946695A (en) 1994-07-08 1996-02-09 Schering Corporation Method for identifying nucleic acids encoding c-fos promoter activating proteins
DE4428402A1 (de) 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US5792647A (en) 1995-02-13 1998-08-11 The Johns Hopkins University Bacterial catabolism of chitin
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
US6254874B1 (en) 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
JP3530676B2 (ja) * 1995-04-26 2004-05-24 キヤノン株式会社 光受容部材の製造方法、該光受容部材、該光受容部材を有する電子写真装置及び該光受容部材を用いた電子写真プロセス
US7364894B2 (en) * 1995-09-15 2008-04-29 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
US5874259A (en) 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector
AU2004244756A1 (en) 2003-06-05 2004-12-16 Centelion Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects

Also Published As

Publication number Publication date
HK1082761B (en) 2012-05-18
US20090252713A1 (en) 2009-10-08
NO20052276D0 (no) 2005-05-10
IL167706A (en) 2012-05-31
NZ539311A (en) 2008-06-30
EP1549735A4 (en) 2006-05-03
US7279313B2 (en) 2007-10-09
PT1549735E (pt) 2011-11-30
RU2005114367A (ru) 2005-12-20
SI1549735T1 (sl) 2011-12-30
KR20050084847A (ko) 2005-08-29
ATE521695T1 (de) 2011-09-15
EP1549735A2 (en) 2005-07-06
AU2003287078B2 (en) 2009-01-15
CA2501851C (en) 2014-03-11
HK1086297A1 (zh) 2006-09-15
KR101323542B1 (ko) 2013-10-29
RU2307870C2 (ru) 2007-10-10
WO2004033664A2 (en) 2004-04-22
AU2009201405A1 (en) 2009-05-07
CY1112110T1 (el) 2015-11-04
DK1549735T3 (da) 2011-12-12
CN101182534A (zh) 2008-05-21
WO2004033664A3 (en) 2004-12-29
CN100491521C (zh) 2009-05-27
US20070015282A1 (en) 2007-01-18
JP2006502714A (ja) 2006-01-26
NO20052276L (no) 2005-07-06
US7807444B2 (en) 2010-10-05
EP1549735B1 (en) 2011-08-24
ZA200503039B (en) 2006-11-29
US20030161844A1 (en) 2003-08-28
CN101182534B (zh) 2013-04-24
CN1717476A (zh) 2006-01-04
AU2003287078A1 (en) 2004-05-04
HK1082761A1 (en) 2006-06-16
CA2501851A1 (en) 2004-04-22
NZ566205A (en) 2009-02-28
MXPA05003857A (es) 2005-06-22
JP4522861B2 (ja) 2010-08-11
ES2372599T3 (es) 2012-01-24
US20070141708A2 (en) 2007-06-21
NO333932B1 (no) 2013-10-21
JP2010057493A (ja) 2010-03-18
JP4750203B2 (ja) 2011-08-17

Similar Documents

Publication Publication Date Title
BR0314512A (pt) Célula hospedeira recombinante procariótica, método para a produção de um plasmìdeo, plasmìdeo e método para a detecção de uma mutação de cópia plasmìdea
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
BRPI9610511B8 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
BRPI0814781A8 (pt) ''proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico descarboxilase''
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
Zhang et al. MiniCAFE, a CRISPR/Cas9-based compact and potent transcriptional activator, elicits gene expression in vivo
EP2330200A3 (en) Gene expression technique
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
WO2006136084A8 (en) Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
PL393644A1 (pl) Komórka gospodarza, sposób wytwarzania polipeptydu w komórce gospodarza, przeciwciała, fragment przeciwciała, fuzja białkowa, kompozycja farmaceutyczna i sposób leczenia nowotworu
EA200701023A1 (ru) Отбор клеток-хозяев, экспрессирующих белок на высоких уровнях
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
ATE486935T1 (de) Mikroorganismenstamm zur produktion von rekombinanten proteinen
Yi et al. Comparative analyses of the transcriptome and proteome of Escherichia coli C321.△ A and further improving its noncanonical amino acids containing protein expression ability by integration of T7 RNA polymerase
Hamashima et al. Nematode-specific tRNAs that decode an alternative genetic code for leucine
BRPI0512798A (pt) molécula de ácido nucleico recombinante, célula, método para produzir uma proteìna de interesse, uso de uma seqüência de ácido nucleico tendo atividade anti-repressora, métodos para gerar uma célula hospedeira expressando dois polipeptìdios de interesse, e para expressar dois polipeptìdios de interesse
WO2006107813A3 (en) Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-trna synthetase
Liu et al. Mutational switching of a yeast tRNA synthetase into a mammalian-like synthetase cytokine
BRPI0414670A (pt) método para preparar uma célula, célula, métodos para fornecer uma célula e para gerar uma batelada de adenovìrus recombinante, molécula recombinante, conjunto de pelo menos duas moléculas de ácido nucleico, e, sistema de empacotamento
WO2004078915A3 (en) Cell culture
BR112023023386A2 (pt) Células engenheiradas para produção aumentada de proteínas de difícil expressão
WO2006097945A3 (en) A method for achieving high-level expression of recombinant human interleukin-2 upon destabilization of the rna secondary structure
DE602005018021D1 (de) Impfstoffe mit ornithobakterium rhinotracheale-untereinheit
Shen et al. Structural and Mechanistic Investigations of a High-Fidelity Cas9 from Parasutterella secunda
TW202617984A (zh) Dna修飾酶及活性片段，及其變異體與使用方法

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2327 DE 11-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI